CSL Behring

03.07.2020 – 08:30
IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Hattersheim, Germany (ots/PRNewswire) - European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® ...
mehr
25.08.2011 – 19:48
CSL Behring Receives European Health Authorities' Approval for Self-Administration of Berinert®
Marburg, Germany (ots/PRNewswire) - - Self-administration of C1-Esterase Inhibitor is now approved in 23 European countries for treatment of Hereditary Angioedema, a rare and sometimes life-threatening condition CSL Behring [http://www.cslbehring.com ] today announced that European health authorities have approved self-administration of Berinert(R), a C1-esterase ...
mehr